SA PRO
Free Account
Veracyte, Inc.VCYTNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 65% recommend buying.

Consensus Rating
Buy
20 analysts·High coverage
65%
Rating Distribution
Strong Buy
00%
Buy
1365%
Hold
630%
Sell
15%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 5, 2026Guggenheim
Veracyte price target raised to $50 from $45 at Guggenheim
Target:$50.00
+16.4%from $42.95
Dec 1, 2025Morgan Stanley
Veracyte assumed with an Underweight at Morgan Stanley
Target:$48.00
+3.5%from $46.39
Nov 5, 2025UBS
Veracyte price target raised to $48 from $42 at UBS
Target:$48.00
+10.0%from $43.64
Nov 5, 2025Canaccord Genuity
Veracyte, Inc (VCYT) PT Raised to $43 at Canaccord Genuity
Target:$43.00
+19.0%from $36.12
Oct 20, 2025Canaccord Genuity
Veracyte initiated with a Hold at Canaccord
Target:$40.00
+11.6%from $35.83
Aug 8, 2025Morgan Stanley
Veracyte price target lowered to $28 from $29 at Morgan Stanley
Target:$28.00
+2.3%from $27.37
Nov 7, 2024Needham
Veracyte, Inc (VCYT) PT Raised to $44 at Needham
Target:$44.00
+22.7%from $35.85
Aug 12, 2024Morgan Stanley
Veracyte price target raised to $26 from $21 at Morgan Stanley
Target:$26.00
-11.6%from $29.41
May 4, 2022Morgan Stanley
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $23
Target:$23.00
+9.5%from $21.00
May 4, 2022Needham
Needham Maintains Buy on Veracyte, Lowers Price Target to $26
Target:$26.00
+21.2%from $21.46

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance